Display options
Cite
Uchida A, Watanabe M, Nawata A, et al. Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN Case Rep. 2017;6(2):169-174doi: 10.1007/s13730-017-0269-y.
Uchida, A., Watanabe, M., Nawata, A., Ikari, Y., Sasaki, M., Shigemoto, K., Hisano, S., & Nakashima, H. (2017). Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN case reports, 6(2), 169-174. https://doi.org/10.1007/s13730-017-0269-y
Uchida, Ai, et al. "Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings." CEN case reports vol. 6,2 (2017): 169-174. doi: https://doi.org/10.1007/s13730-017-0269-y
Uchida A, Watanabe M, Nawata A, Ikari Y, Sasaki M, Shigemoto K, Hisano S, Nakashima H. Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN Case Rep. 2017 Nov;6(2):169-174. doi: 10.1007/s13730-017-0269-y. Epub 2017 Aug 28. PMID: 28849361; PMCID: PMC5694406.
Copy Download .nbib Format: NLM
Share it on

CEN Case Rep. 2017 Nov;6(2):169-174. doi: 10.1007/s13730-017-0269-y. Epub 2017 Aug 28.

Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings.

CEN case reports

Ai Uchida, Maho Watanabe, Aya Nawata, Yosuke Ikari, Masaru Sasaki, Kana Shigemoto, Satoshi Hisano, Hitoshi Nakashima

Affiliations

  1. Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. [email protected].
  2. Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
  3. Division of Pathology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
  4. Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.

PMID: 28849361 PMCID: PMC5694406 DOI: 10.1007/s13730-017-0269-y

Abstract

Immune-checkpoint inhibitor nivolumab (anti-PD-1 antibody) blocks T cell inhibition and stimulate immunologic response toward cancer cells. It was also revealed that PD-1/PD-L1 interaction crucially controls the effector differentiation of auto-reactive T cells to maintain self-tolerance. Therefore, potential autoimmunological side-effect can occur in any organ. Here, we report a case of 67-year-old Japanese male with lung adenocarcinoma treated with nivolumab who developed acute tubulointerstitial nephritis after the third infusion of nivolumab. Kidney biopsy showed distinct histological findings: Proliferation of CD38 positive and IgG positive plasma cells, and affluent infiltration of FoxP3

Keywords: Anti-programmed cell death-1; FoxP3; Immune-checkpoint inhibitor; Nivolumab; Tubulointerstitial nephritis

References

  1. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
  2. J Immunol. 2011 Jul 15;187(2):861-9 - PubMed
  3. Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8490-5 - PubMed
  4. Kidney Int. 2005 Nov;68(5):2091-102 - PubMed
  5. Nat Immunol. 2005 Mar;6(3):280-6 - PubMed
  6. Am J Kidney Dis. 2016 Aug;68(2):287-291 - PubMed
  7. Oncotarget. 2015 Feb 28;6(6):3479-92 - PubMed
  8. Nephrol Dial Transplant. 2004 Nov;19(11):2713-20 - PubMed
  9. Mod Rheumatol. 2015 Jul;25(4):571-8 - PubMed
  10. J Immunol. 2006 Dec 15;177(12):8291-5 - PubMed
  11. J Exp Med. 2000 Oct 2;192(7):1027-34 - PubMed
  12. Ann Pharmacother. 2015 Aug;49(8):907-37 - PubMed
  13. Nat Immunol. 2014 Nov;15(11):1070-8 - PubMed
  14. Annu Rev Pathol. 2008;3:189-220 - PubMed
  15. Nat Med. 1999 Dec;5(12):1365-9 - PubMed
  16. N Engl J Med. 2015 Jul 9;373(2):123-35 - PubMed
  17. N Engl J Med. 2015 May 21;372(21):2018-28 - PubMed
  18. Cancer Treat Rev. 2016 Mar;44:51-60 - PubMed
  19. Clin Immunol. 2005 May;115(2):184-91 - PubMed

Publication Types